Extracorporeal membrane oxygenation for overwhelming Blastomyces dermatitidis pneumonia

Dalton, Heidi J.; Hertzog, James H.; Hannan, Robert L.; Vezza, Phyllis R.; Hauser, Gabriel J.

doi:10.1186/cc349

Cited by 13 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extracorporeal membrane oxygenation (ECMO) has also been used in the management of patients with blastomycosis-associated ARDS. Published data to support this practice come from small case series and case reports that have shown variable clinical response [ 69 , 70 , 71 , 72 , 73 ]. In one report, occlusion of the ECMO circuit during the administration of liposomal amphotericin B was noted and was associated with an unfavorable outcome [ 73 ].…”

Section: Treatmentmentioning

confidence: 99%

Blastomycosis: A Review of Mycological and Clinical Aspects

Linder

Kauffman

Miceli

2023

JoF

View full text Add to dashboard Cite

Blastomycosis is caused by a thermally dimorphic fungus that thrives in moist acidic soil. Blastomyces dermatitidis is the species responsible for most infections in North America and is especially common in areas around the Great Lakes, the St. Lawrence Seaway, and in several south-central and southeastern United States. Other Blastomyces species have more recently been discovered to cause disease in distinct geographic regions around the world. Infection almost always occurs following inhalation of conidia produced in the mold phase. Acute pulmonary infection ranges from asymptomatic to typical community-acquired pneumonia; more chronic forms of pulmonary infection can present as mass-like lesions or cavitary pneumonia. Infrequently, pulmonary infection can progress to acute respiratory distress syndrome that is associated with a high mortality rate. After initial pulmonary infection, hematogenous dissemination of the yeast form of Blastomyces is common. Most often this is manifested by cutaneous lesions, but osteoarticular, genitourinary, and central nervous system (CNS) involvement also occurs. The diagnosis of blastomycosis can be made by growth of the mold phase of Blastomyces spp. in culture or by histopathological identification of the distinctive features of the yeast form in tissues. Detection of cell wall antigens of Blastomyces in urine or serum provides a rapid method for a probable diagnosis of blastomycosis, but cross-reactivity with other endemic mycoses commonly occurs. Treatment of severe pulmonary or disseminated blastomycosis and CNS blastomycosis initially is with a lipid formulation of amphotericin B. After improvement, therapy can be changed to an oral azole, almost always itraconazole. With mild to moderate pulmonary or disseminated blastomycosis, oral itraconazole treatment is recommended.

show abstract